(Q34481692)

2 August 2017

1 reference

title

Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus (English)

1 reference

2 August 2017

1 reference

B Nyholm

1

1 reference

2 August 2017

B Brock

series ordinal

2

1 reference

2 August 2017

L Ørskov

series ordinal

3

1 reference

2 August 2017

O Schmitz

series ordinal

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

1641-1652

1 reference

Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Islet amyloid and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Co-secretion of amylin and insulin from cultured islet β-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Role of islet amyloid polypeptide secretion in insulin-resistant humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Vagal control of digestion: modulation by central neural and peripheral endocrine factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

The molecular pharmacology of CGRP and related peptide receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Effects of islet amyloid polypeptide on hepatic insulin resistance and glucose production in the isolated perfused rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Amylin and the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Effects of amylin on appetite regulation and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Reduction of food intake in rats by intraperitoneal injection of low doses of amylin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Postprandial blood glucose. American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Carbohydrate metabolism in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Relationships of upper gastrointestinal motor and sensory function with glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

21 January 2018

A drug on the market?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1641

10.1517/13543784.10.9.1641

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference